Top Page
SAB Biotherapeutics
(NASDAQ:SABS)
SAB Biotherapeutics (SABS) vs. SPDR S&P 500 ETF (SPY)
SAB Biotherapeutics Business Overview & Revenue Model
SAB Biotherapeutics Financial Statement Overview
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 1.32M | 2.24M | 23.90M | 60.88M |
| Gross Profit | -3.08M | -3.47M | -1.51M | 20.61M | 59.22M |
| EBITDA | -45.87M | -28.99M | -38.13M | -15.12M | -15.20M |
| Net Income | 13.27M | -34.11M | -42.19M | -18.74M | -17.14M |
Balance Sheet | |||||
| Total Assets | 172.81M | 44.20M | 83.94M | 50.90M | 81.14M |
| Cash, Cash Equivalents and Short-Term Investments | 96.59M | 20.76M | 56.57M | 15.05M | 33.21M |
| Total Debt | 5.95M | 4.67M | 5.91M | 5.93M | 8.52M |
| Total Liabilities | 21.32M | 18.23M | 26.64M | 19.85M | 42.59M |
| Stockholders Equity | 151.49M | 25.97M | 57.30M | 31.06M | 38.55M |
Cash Flow | |||||
| Free Cash Flow | -45.71M | -34.63M | -25.32M | -25.63M | -8.96M |
| Operating Cash Flow | -44.78M | -34.29M | -25.12M | -23.46M | 1.99M |
| Investing Cash Flow | -121.71M | -11.96M | -152.70K | -2.09M | -10.94M |
| Financing Cash Flow | 168.30M | -1.17M | 66.77M | 1.05M | 35.89M |
SAB Biotherapeutics Technical Analysis
SAB Biotherapeutics Risk Analysis
SAB Biotherapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $46.92M | -3.44 | -21.17% | ― | 12.71% | 79.93% | |
54 Neutral | $35.57M | -1.32 | -152.90% | ― | ― | 3.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $45.25M | -0.97 | -84.39% | ― | ― | 15.32% | |
51 Neutral | $39.81M | -0.65 | -80.00% | ― | ― | 9.63% | |
50 Neutral | $191.07M | -1.07 | -21.16% | ― | -92.42% | 62.37% |
SAB Biotherapeutics Corporate Events
On March 17, 2026, SAB Biotherapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 19,324,677 shares of common stock and pre-funded warrants for up to 2,753,246 additional shares, all sold by the company at a public price of $3.85 per share or $3.8499 per pre-funded warrant, with a 30-day option for underwriters to buy up to 3,311,688 additional shares. The offering, expected to close on March 19, 2026 under an effective shelf registration, is anticipated to generate about $69.7 million in net proceeds, or $81.7 million if the overallotment is fully exercised, providing SAB with substantial capital to advance its SAB-142 clinical program, manufacturing, regulatory and operational activities, and general corporate purposes.
SAB BIO announced on March 17, 2026 that Jefferies, UBS Investment Bank, Citigroup, and Barclays are acting as joint bookrunners, with Chardan as lead manager, for this equity raise. By bolstering its balance sheet through a sizable primary equity issuance, the company is reinforcing its ability to fund ongoing and planned trials in type 1 diabetes and other autoimmune indications, a move that may dilute existing shareholders but supports its longer-term growth and development pipeline.
The most recent analyst rating on (SABS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
On March 10, 2026, SAB Biotherapeutics, Inc. reported additional Phase 1 data for its fully human anti-thymocyte globulin candidate SAB-142 in adults with established autoimmune type 1 diabetes. The company simultaneously made a detailed data presentation and an expert webinar by T1D key opinion leader Michael J. Haller available to clinicians and investors.
In the Phase 1 HUMAN trial’s established T1D cohort of six adults, four patients who received SAB-142 at 2.5 mg/kg showed preserved, and on average slightly increased, C-peptide levels at Day 120 versus baseline, while the placebo participant who completed follow-up showed a decline consistent with expected disease progression. These exploratory signals, supported by biomarker evidence of T cell exhaustion, build on earlier safety and pharmacodynamic results and underpin SAB BIO’s decision to advance SAB-142 into the ongoing registrational Phase 2b SAFEGUARD trial in newly diagnosed Stage 3 T1D across adults, adolescents, and children.
By diverging from both the study placebo subject and a modeled historical placebo cohort from the TN19 trial, SAB-142’s early pharmacodynamic profile suggests potential preservation of beta cell function in established T1D. For stakeholders, the data offer incremental clinical validation of SAB-142’s mechanism and reinforce SAB BIO’s positioning as a contender in disease-modifying therapies for type 1 diabetes, while the active global enrollment in SAFEGUARD signals a clear path toward later-stage efficacy readouts.
The most recent analyst rating on (SABS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
On January 12, 2026, SAB Biotherapeutics posted an updated corporate presentation outlining strong 2025 execution and a multi‑year clinical and financial roadmap centered on SAB‑142 for newly diagnosed Stage 3 Type 1 diabetes. The company reported that its registrational Phase 2b SAFEGUARD trial is expected to begin dosing in late 2025, complete enrollment by the end of 2026, and deliver topline data in the second half of 2027, supported by prior MELD and Phase 1 data indicating efficacy signals and a favorable safety profile without lymphodepletion or immunogenicity on redosing; with $144 million in cash and equivalents as of December 31, 2025 and projected runway through 2028, SAB Biotherapeutics signaled it is well funded to advance SAB‑142 within an expanding, clearly regulated T1D treatment landscape shaped by precedent therapies such as Tzield.
The most recent analyst rating on (SABS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
On January 5, 2026, SAB Biotherapeutics appointed veteran biopharma executive David Zaccardelli, Pharm.D., and rheumatologist and drug development leader Rita Jain, M.D., as Class II directors, with Zaccardelli becoming Chair of the Board and both serving until the 2026 annual meeting. The appointments, announced publicly on January 7, 2026, follow RA Capital Healthcare Fund’s nomination rights stemming from SAB’s July 2025 private placement and keep CEO Samuel J. Reich on the board while shifting the chair role to an independent industry operator with a track record of leading companies through major growth, approvals, and M&A. Both Zaccardelli and Jain bring deep experience in late-stage development, commercialization, and autoimmune and inflammatory disease drug development, signaling SAB BIO’s intent to strengthen governance and board-level expertise as it advances its lead asset SAB-142 through registrational trials and prepares for potential commercialization in type 1 diabetes, a move likely to be closely watched by investors focused on execution risk and value creation in autoimmune therapeutics.
The most recent analyst rating on (SABS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.
On December 29, 2025, SAB Biotherapeutics, Inc. entered into a new sales agreement with UBS Securities LLC to establish an at-the-market equity offering program allowing the company to issue and sell up to $75 million of its common stock from time to time on Nasdaq at prevailing market prices, with proceeds intended to support its development pipeline and general corporate purposes. This new program, under which SAB will pay UBS up to 3% of gross proceeds per share sale and which either party can terminate on ten days’ notice, follows the company’s December 17, 2025 termination of its prior $20 million at-the-market arrangement with Cantor Fitzgerald & Co., which ended without any associated costs or payments and cleared the way for the larger UBS-led facility.
The most recent analyst rating on (SABS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.